Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P05160
UPID:
F13B_HUMAN
Alternative names:
Fibrin-stabilizing factor B subunit; Protein-glutamine gamma-glutamyltransferase B chain; Transglutaminase B chain
Alternative UPACC:
P05160; A8K3E5; Q5VYL5
Background:
The Coagulation factor XIII B chain, known alternatively as Fibrin-stabilizing factor B subunit, Protein-glutamine gamma-glutamyltransferase B chain, and Transglutaminase B chain, plays a crucial role in blood coagulation. It stabilizes the A subunits and regulates the formation of transglutaminase, a key enzyme in the coagulation process.
Therapeutic significance:
Factor XIII subunit B deficiency, a rare hematologic disorder, manifests as a life-long bleeding tendency, impaired wound healing, and spontaneous abortion in women. This condition underscores the therapeutic potential of targeting the Coagulation factor XIII B chain for innovative treatments.